Applied Molecular Transport Announces Upcoming Investor Events in September and October
September 17 2021 - 8:00AM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced that the
company will participate in the following investor events in
September and October.
Details of the events are as follows:
Event: SVB CyberRx Series:
Neuromuscular, Rare Diseases & Genetic Medicines 1x1
EventFormat: 1x1 Investor
meetingsDate: September 22-23, 2021
Event: Research &
Development DayFormat: Virtual meeting hosted by
AMT Management with key IBD and rheumatology opinion leaders, Brian
Feagan, MD and Peter Lipsky, MDDate: October 15,
2021Time: 8am – 11am PT
Event: Jefferies 2nd Annual
Next Generation IBD Therapeutics SummitFormat:
Fireside chat with Tahir Mahmood, Ph.D., chief executive officer
and co-founder, and 1x1 Investor meetingsDate:
October 19, 2021
Live webcasts for the company’s Research &
Development Day and fireside chat at the Jefferies 2nd Annual Next
Generation IBD Therapeutics Summit will be accessible via the
Events page of the Applied Molecular Transport website at
https://ir.appliedmt.com/news-events/events. Archived replays will
be available for 30 days following the event.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a
clinical-stage biopharmaceutical company leveraging its proprietary
technology platform to design and develop a pipeline of novel oral
biologic product candidates to treat autoimmune, inflammatory,
metabolic, and other diseases. AMT’s proprietary technology
platform allows it to exploit existing natural cellular trafficking
pathways to facilitate the active transport of diverse therapeutic
modalities across the intestinal epithelial (IE) barrier. Active
transport is an efficient mechanism that uses the cell’s own
machinery to transport materials across the IE barrier. AMT
believes that its ability to exploit this mechanism is a key
differentiator of its approach. AMT is developing additional oral
biologic product candidates in patient-friendly oral forms that are
designed to either target local gastrointestinal tissue or enter
systemic circulation to precisely address the relevant biology of a
disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:Andrew ChangHead,
Investor Relations & Corporate
Communicationsachang@appliedmt.com
Media Contacts:Alexandra SantosWheelhouse Life
Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024